SAB Biotherapeutics to Go Public via Merger with Big Cypress Acquisition Corp.

Ensysce Biosciences Acquires Cy Biopharma

August 6, 2026

Biotechnology

Ensysce Biosciences completed its acquisition of Cy Biopharma in a stock-for-stock merger. Concurrently, Ensysce entered into a definitive private placement financing expected to raise about $21.5 million at initial close, plus an additional up to $38.6 million upon a clinical milestone, to fund development of Cy Biopharma’s lead program CY200 for complex regional pain syndrome.

Boundless Bio and Serapha Bio Announce Merger and $230 Million Private Placement

June 25, 2026

Biotechnology

Boundless Bio and Serapha Bio entered into a definitive agreement to merge in an all-stock transaction. Serapha will combine with Boundless Bio, with the combined company expected to operate as Serapha Bio and trade on Nasdaq under ticker AATD, following a pre-closing $230 million private investment led by RA Capital Management and RTW Investments.

Korsana Biosciences Merges with Cyclerion Therapeutics

April 1, 2026

Biotechnology

Korsana Biosciences and Cyclerion Therapeutics entered into an all-stock merger agreement, with the combined company to operate as Korsana Biosciences and focus on advancing Korsana’s neurodegenerative disease pipeline. The merger was completed on September 8, 2026; a concurrent $380 million private placement was completed immediately before closing to fund operations and clinical milestones.

GlycoMimetics to Acquire Crescent Biopharma (Merger to Operate as Crescent Biopharma, Inc.)

October 29, 2024

Healthcare Services

GlycoMimetics entered into an acquisition agreement with privately held oncology-focused biotechnology company Crescent Biopharma. The combined company will operate under the name Crescent Biopharma, Inc., advancing Crescent’s precision-engineered biologics for solid tumors, including the lead program CR-001, alongside ADC programs CR-002 and CR-003, supported by approximately $200 million in committed financing. GlycoMimetics stockholders approved the proposed merger in June 2025, and the combined company is expected to begin trading on Nasdaq on June 16, 2025 under the new ticker.

Cybin Inc. Acquires Small Pharma Inc.

August 28, 2023

Biotechnology

Cybin Inc. has agreed to acquire all issued and outstanding securities of U.K.-based Small Pharma in an all‑share plan of arrangement. The transaction combines Cybin's and Small Pharma's clinical-stage psychedelic therapeutic programs and IP into a single, publicly traded clinical‑stage biopharmaceutical company headquartered in Toronto.

OceanTech Acquisitions I Corp and Captura Biopharma Sign Definitive Business Combination Agreement

August 10, 2022

Biotechnology

OceanTech Acquisitions I Corp., a special purpose acquisition company, signed a definitive merger agreement with Captura Biopharma to take the biotech company public. The combined company is expected to operate under the name Captura Biopharma Holdings, Inc. and remain listed on Nasdaq, subject to SEC, regulatory, and stockholder approvals.